Johnson & Johnson is earmarking over $2 billion to build a new biologics manufacturing facility in Wilson, NC, for a variety of therapies for oncology, immunology and neuroscience.
Construction of the new facility is anticipated to begin in the first half of 2025 and, as well as making biologics, it will also focus on using technology to make manufacturing processes more “efficient,” the company said in a Tuesday press release.
The new facility will hire an additional 420 employees. Available positions will include analysts, engineers, microbiologists, scientists, specialists, managers and more senior leadership roles, according to a statement from North Carolina Gov. Roy Cooper on the same day J&J announced the new build.
J&J is also set to potentially receive some funding from North Carolina. The state’s Economic Investment Committee may reimburse J&J up to nearly $13.7 million over the next 12 years, but this is dependent on J&J meeting several targets, including creating jobs and “investment targets,” per the release.
Further, J&J could receive a $1.5 million grant from the One North Carolina Fund, but this is also contingent on the company meeting job creation milestones.